HYBIO(SZ:300199) Zheng Quan Shi Bao Wang·2025-06-09 12:02Core Viewpoint - The collaboration between Hanyu Pharmaceutical and Carbon Cloud Peptide aims to develop innovative peptide drugs targeting metabolic diseases, marking a significant milestone in the HY3003 project [1][2]. Group 1: Project Development - The HY3003 project has successfully completed the screening of optimal candidate compounds and the development of raw material processes, now entering the raw material pilot scale-up phase [1][2]. - The project is advancing multiple dosage forms, including weekly, monthly, and oral formulations, with a focus on reducing administration frequency and improving patient compliance [2]. Group 2: Collaboration Details - Hanyu Pharmaceutical and Carbon Cloud Peptide signed a joint development agreement for the GLP-1R/GIPR/GCGR triple agonist, with Hanyu responsible for preclinical research, IND application, clinical trials, and product registration [1]. - Hanyu will pay up to 38 million yuan in milestone payments to Carbon Cloud Peptide, and will share revenue based on sales, with a maximum of 10% in North America and 3% in other global regions [1]. Group 3: Strategic Implications - This collaboration is expected to enhance Hanyu's innovation capabilities and product diversity in the treatment of metabolic diseases, laying a solid foundation for long-term development in the healthcare sector [2]. - The progress of HY3003 reflects Hanyu's technological advancements in the "AI + peptide" integration model, showcasing the company's expertise in peptide raw materials, formulation processes, and platform technologies [2].